-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-106 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-106 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Follicular Lymphoma Drug Details: MB-106 is under investigation for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Vulvar Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Vulvar Cancer Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cusatuzumab in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cusatuzumab in Solid Tumor Drug Details: Cusatuzumab (ARGX-110) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cusatuzumab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cusatuzumab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Cusatuzumab (ARGX-110) is under development for the...
-
Product Insights
NewAcute Promyelocytic Leukemia – Drugs In Development, 2024
Empower your strategies with our Acute Promyelocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Acute Promyelocytic Leukemia is an aggressive blood cancer affecting the white blood cells known as promyelocytes which are immature white blood cells. It is characterized by thrombocytopenia (low platelets) resulting in thrombosis, excess bleeding, and anemia. It is a sub type of AML (acute myeloid leukemia) and is a medical emergency condition. Infections, bruises, bleeding are common symptoms and when examined...
-
Product Insights
NewWaldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
NewCutaneous T-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
NewAngioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024
Empower your strategies with our Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024 report and make more profitable business decisions. Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections....
-
Product Insights
NewPeripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024
Empower your strategies with our Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral T-cell lymphomas (PTCL) constitute a diverse group of rare and aggressive non-Hodgkin lymphomas originating from mature T cells. These malignancies involve lymphoid tissues and may affect organs throughout the body. PTCLs are heterogeneous, comprising various subtypes with distinct clinical behaviors and outcomes. Symptoms may include enlarged lymph nodes, fever, weight loss, and night sweats. Diagnosis involves biopsies, imaging studies,...